This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Nice Relief Rally on Biotech Assurances, Home Sales Data
by Mark Vickery
The Dow crossed back north of 35K, +236 points or +0.68%, while the S&P 500 put up its best trading day in six weeks.
Nice Relief Rally on Biotech Assurances, Home Sales Data
by Mark Vickery
The Dow crossed back north of 35K, +236 points or +0.68%, while the S&P 500 put up its best trading day in six weeks.
Omicron Fears Fuel Rally in Vaccine Stocks: Will It Continue?
by Zacks Equity Research
Another variant of the coronavirus, Omicron, is up on the WHO-identified list. Several mutations of this variant spark fears of high resistance to the COVID-19 vaccines.
Novavax (NVAX) Stock Up YTD on COVID-19 Vaccine Potential
by Zacks Equity Research
Novavax (NVAX) is likely to generate huge revenues as the company has started filing approvals for emergency use of its COVID-19 vaccine in multiple nations.
Are Options Traders Betting on a Big Move in Novavax (NVAX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.
Novavax (NVAX) COVID Jab Gets Philippines Nod, Under Review in EU
by Zacks Equity Research
Novavax's (NVAX) secures approval for its COVID vaccine in the Philippines. The EMA begins reviewing the company's regulatory submission for its COVID vaccine. Evidently, the stock gains.
Novavax's (NVAX) Q3 Loss Widens, Revenues Lag Estimates
by Zacks Equity Research
Novavax (NVAX) reports wider-than-expected loss for the third quarter of 2021 while revenues miss estimates. Shares down.
Novavax (NVAX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Novavax (NVAX) delivered earnings and revenue surprises of -6.68% and -41.71%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Drug, Biotech Stock Q3 Earnings on Nov 4: MRNA, REGN & More
by Zacks Equity Research
Let us take a look at five drug/biotech companies due to release their quarterly results on Nov 4.
Novavax (NVAX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On Novavax's (NVAX) upcoming third-quarter earnings call, investor focus is likely to be on the company's progress with its COVID-19 vaccine candidate NVX-CoV2373.
Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed at $148.83 in the latest trading session, marking a -1.19% move from the prior day.
Earnings Preview: Novavax (NVAX) Q3 Earnings Expected to Decline
by Zacks Equity Research
Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed the most recent trading day at $138.79, moving +1.41% from the previous trading session.
Novavax (NVAX) Down on COVID Jab-Manufacturing Problem Reports
by Zacks Equity Research
Novavax's (NVAX) shares fall on reports of the company's manufacturing problems related to its COVID-19 vaccine candidate.
Novavax (NVAX) Lags in COVID Vaccine Race: Will It Gather Pace?
by Zacks Equity Research
Novavax (NVAX) is progressing well with its COVID-19 and flu vaccines. However, it is lagging in the COVID-19 vaccine space. Let us see how the company is likely to perform going forward.
Novavax (NVAX) Concentrates on COVID-19 Vaccine Development
by Zacks Equity Research
While Novavax's (NVAX) COVID-19 vaccine shows potential, delay in regulatory filings in both the United States and Europe does not bode well for the stock.
Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for EUSA
3 Drugmakers in Focus After Merck's Positive COVID-19 Pill Data
by Zacks Equity Research
Here we discuss three other pharma or biotech companies with promising oral drug candidates for treating COVID-19 following Merck's (MRK) announcement of promising clinical data on its oral therapy.
Vaccine Stocks Down Following Merck's COVID-19 Pill Success
by Kinjel Shah
Stocks of several COVID-19 vaccine makers declined on Friday after Merck (MRK) released positive data for a new oral antiviral treatment for COVID-19
J&J (JNJ) Starts Phase III Study on RSV Vaccine in Older Adults
by Zacks Equity Research
J&J (JNJ) starts the phase III study on its RSV vaccine candidate in adults aged 60 years and above.
Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed the most recent trading day at $203.53, moving -0.63% from the previous trading session.
Biotech Stock Roundup: XLRN Up on Takeover Rumor, NVAX, BIIB Offer Updates & More
by Zacks Equity Research
Regulatory and pipeline updates from bigwigs like Biogen (BIIB) and Novavax (NVAX) have been some of the key highlights in the biotech sector during the past week.
Novavax (NVAX) Applies to WHO for COVID-19 Vaccine Listing
by Zacks Equity Research
On being granted the emergency use listing for Novavax's (NVAX) COVID-19 vaccine by WHO, it is to become eligible to supply the same to numerous countries participating through the COVAX facility
Novavax (NVAX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed at $230.29 in the latest trading session, marking a +1.49% move from the prior day.
Pfizer, Moderna Support COVID Vaccine Booster Before FDA Meet
by Zacks Equity Research
Amid rising coronavirus cases, PFE and MRNA are trying to make booster doses of their COVID-19 vaccine available for US citizens. An FDA meeting is scheduled tomorrow to discuss Comirnaty's booster dose.